ColonSentry is a blood-based test designed to find out person’s current risk for colorectal cancer.

GeneNews mainly focuses on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers.

The company has a patented core platform technology – Sentinel principle – which can detect and stage virtually any disease or medical condition from a simple blood sample.

GeneNews president and COO Gailina Liew said they believe that commercial success in Malaysia, will help in facilitating the commercial expansion of the ColonSentry test throughout this part of the world.